Valentino joins Alpharma
This article was originally published in The Tan Sheet
Michael Valentino steps into newly created role of president & COO of Global Human Pharmaceuticals and exec VP of firm effective Oct. 15. He reports to Alpharma President & CEO Ingrid Wiik, who says Valentino will help to develop firm's "global growth opportunities by creating and expanding key strategic alliances [and] developing a strong global new product pipeline." Valentino most recently served as Novartis Consumer Health global head/exec VP and also was chairman of CHPA's board (1"The Tan Sheet" Jan. 7, 2002, p. 3)...
You may also be interested in...
Novartis exec Michel Orsinger has taken the reigns as head of the firm's consumer health global OTC division, effective Jan. 1
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.